Comorbidity and polypharmacy burden among people living with HIV in the United States stratified by age, sex, and race: updated evidence from a contemporary cohort

BACKGROUND: Advances in antiretroviral therapy (ART) have extended the life expectancy of people living with HIV, increasing the prevalence of comorbidities and polypharmacy burden. OBJECTIVE: To compare comorbidity burden and polypharmacy among people living with HIV and matched people without HIV stratified by age, sex, and race/ethnicity. METHODS: This retrospective study used claims data from Optum's de-identified Clinformatics® Data Mart Database (01/01/19-12/31/24). Adults (≥18 years) with ≥1 ART claim or HIV diagnosis code during the 2024 calendar year (index date: earliest ART or HIV claim) were matched 2:1 to adults without HIV by age group, sex, race, region, and insurance type. Continuous enrolment of 12 months pre-index (baseline) and ≥30 days post-index was required. Baseline comorbidities and polypharmacy were compared between the two cohorts. . RESULTS: < 0.001). Multimorbidity (≥2 non-HIV comorbidities) and polypharmacy (≥5 non-ART drugs) prevalence were significantly higher among people living with HIV and increased with age and among females. Similar patterns were observed across racial/ethnic groups. CONCLUSIONS: People living with HIV had greater comorbidity and polypharmacy burden than matched people without HIV across demographic subgroups. These findings underscore the need for comprehensive comorbidity assessment and comedication review to minimise drug interactions and support optimal treatment decisions for people living with HIV.